University Of Maryland Medical Center Performs First Atrial Defibrillation Implant In Mid-Atlantic Region

October 22, 1997

(Baltimore) -- Doctors at the University of Maryland Medical Center have performed the first implantation in the mid-Atlantic region of a new device to shock a rapidly beating heart back into normal rhythm. The device is the first designed to treat atrial fibrillation, an abnormally fast rhythm in the upper chamber of the heart, which is the leading cause of hospitalization, and the costliest, for those with irregular heart beats.

The implantation in Charles Brining, 58, a Hagerstown machine operator, was conducted Oct. 7 by cardiologists Stephen Shorofsky, M.D., Ph.D, and Michael R. Gold, M.D., Ph.D., director of the electrophysiology lab at the University of Maryland Medical Center.

Only 27 of these implants have been done so far, and this was the first in the mid-Atlantic region including Maryland, Delaware, Pennsylvania and the District of Columbia. The procedure was part of a Phase I study approved by the Food and Drug Administration to investigate the safety and efficacy of the device.

The device, made by InControl, Inc., of Redmond, WA, fits under the skin at the top of the chest, with lead wires attached to the heart through a vein under the collarbone. It is about the size of a deck of cards and delivers a small electrical shock to regulate a dangerously rapid heartbeat.

Until development of the new device, external shocks delivered through patches attached to the skin were performed in a hospital. "This is an implantable device that will do it automatically and internally, with an option for the patient to control its use and receive therapy outside the hospital," Gold says.

Implants of ventricular defibrillating devices have been done for about 10 years in patients with life-threatening arrhythmia in the lower chamber of the heart, called the ventricle. The new device was developed when it became possible to use less energy to defibrillate the heart, making the procedure more comfortable for the patient.

The device, called the Metrix System TM, operates in three different modes: automatic, in which it delivers a warning and then therapy when arrhythmia is detected; monitor mode, in which it is activated by a physician in an office or hospital; and patient-activated, in which the wearer self-administers the shock. The batteries should last four or five years.

Mr. Brining says he has had atrial fibrillation for several years. "At first, I didn't notice it. But after a while longer, I was out of breath and feeling run-down," he says. He was referred by his local physician to the University of Maryland Medical Center after external electric shocks and standard medications were not effective.

Atrial fibrillation is the most common heart rhythm disorder and can cause up to a 30 percent reduction in the pumping output of the heart. Symptoms include shortness of breath, palpitations, lightheadedness, fainting, fatigue and reduced exercise capacity. Medications prevent recurrent episodes in only about half of patients.

Although atrial fibrillation is not immediately life-threatening by itself, those who have it are five times more likely to have a stroke than those with normal heart rhythms, and of those who do, 70 percent die or suffer severe brain damage. The cost to the U.S. healthcare system of atrial fibrillation in 1994 was more than $1.3 billion.

University of Maryland Medical Center

Related Atrial Fibrillation Articles from Brightsurf:

Atrial fibrillation less deadly than it used to be, but still cause for concern: BU study
A first-of-its-kind study by researchers from the Boston University School of Public Health (BUSPH) shows a decline in deaths related to atrial fibrillation (irregular heartbeat) over the last 45 years.

Postoperative atrial fibrillation does not impact on overall survival after esophagectomy
Volume 11, Issue 25 of Oncotarget reported that Administration of landiolol hydrochloride was found to be associated with reduced incidence of atrial fibrillation after esophagectomy for esophageal cancer in our previous randomized controlled trial.

People with atrial fibrillation live longer with exercise
More than 100,000 Norwegians have atrial fibrillation. They should be actively exercising for their health.

Atrial fibrillation among overweight people is not due to fat
In a recently published study, researchers from Aarhus University document that the risk of atrial fibrillation is not linked to the amount of body fat, but instead to large muscle mass, or more precisely, a high fat-free weight

Eating more protein could help ward off atrial fibrillation in women
Women who ate slightly more than the recommended daily amount of protein were significantly less likely to develop atrial fibrillation (AFib), a dangerous heart rhythm disorder that can lead to stroke and heart failure, when compared with those who consumed less protein, according to research being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Zebrafish teach researchers more about atrial fibrillation
Genetic research in zebrafish at the University of Copenhagen has surprised the researchers behind the study.

Personalized medicine for atrial fibrillation
The study, published in Europace, uses signals from implantable devices -- pacemakers and defibrillators -- to analyze electrical signals in the heart during episodes of atrial fibrillation.

Prescribing anticoagulants in the ED for atrial fibrillation increases long-term use by 30%
Patients prescribed anticoagulants after a diagnosis of atrial fibrillation in the emergency department are more likely to continue long-term use of medications to treat the condition, according to research published in CMAJ (Canadian Medical Association Journal).

Anticoagulant benefits for atrial fibrillation decrease with age
The net clinical benefit of anticoagulants for atrial fibrillation (AF) -- one of the most important causes of irregular heartbeats and a leading cause of stroke -- decreases with age, as the risk of death from other factors diminishes their benefit in older patients, according to a study led by researchers at UC San Francisco.

Research improves understanding of mechanism of atrial fibrillation
Mouse model studies show that noncoding DNA regions linked to atrial fibrillation risk can display long-range regulatory functions directed at Pitx2 gene and in this way predispose to the condition.

Read More: Atrial Fibrillation News and Atrial Fibrillation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.